Jason Tardio

Jason Tardio is chief operating officer and joined Ovid in November 2019, as chief commercial officer. Prior to joining the Company, Mr. Tardio served as vice president, head of the multiple sclerosis franchise at Novartis (NYSE: NVS). There, he was responsible for developing and managing all aspects of the U.S. commercial plan, brand P&L, strategy development and go-to-market modeling. Before Novartis, Mr. Tardio held roles of increasing responsibility at Biogen (NASDAQ: BIIB), where most recently he served as general manager, managing director for Biogen’s Latin America South affiliate. Earlier at Biogen, Tardio held a wide range of sales and marketing roles of increasing responsibility, including positions in global commercial strategy, the U.S. business unit and the international affiliates. He has two decadesof commercial experience in the biopharmaceutical industry, which began at Wyeth and Sepracor, with roles in sales, sales training and marketing. Mr. Tardio holds a Bachelor of Science from The College of New Jersey and a Master in Business Administration in Pharmaceutical Marketing from St. Joseph’s University.